Ramipril

Generic Name
Ramipril
Brand Names
Altace, Altace HCT
Drug Type
Small Molecule
Chemical Formula
C23H32N2O5
CAS Number
87333-19-5
Unique Ingredient Identifier
L35JN3I7SJ
Background

Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

Indication

For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy.

Associated Conditions
Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event
Associated Therapies
-

Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions

Not Applicable
Completed
Conditions
First Posted Date
2008-06-20
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
39
Registration Number
NCT00702091
Locations
🇺🇸

CEDRA Clinical Research, LLC, Austin, Texas, United States

The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria

First Posted Date
2008-05-08
Last Posted Date
2008-05-08
Lead Sponsor
Gulhane School of Medicine
Target Recruit Count
60
Registration Number
NCT00674596
Locations
🇹🇷

Gulhane School of Medicine, Ankara, Turkey

Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-04-14
Last Posted Date
2011-08-22
Lead Sponsor
Medical University of Vienna
Target Recruit Count
18
Registration Number
NCT00657865
Locations
🇦🇹

Medical University Vienna, Department of Clinical Pharacology, Vienna, Austria

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

First Posted Date
2008-03-10
Last Posted Date
2011-07-12
Lead Sponsor
Novartis
Target Recruit Count
774
Registration Number
NCT00631917
Locations
🇪🇸

Investigative Site, Investigative Site, Spain

The RAS, Fibrinolysis and Cardiopulmonary Bypass

First Posted Date
2008-02-06
Last Posted Date
2012-10-10
Lead Sponsor
Vanderbilt University
Target Recruit Count
111
Registration Number
NCT00607672
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

🇺🇸

TN Valley Healthcare System, Nashville, Tennessee, United States

Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2008-02-06
Last Posted Date
2017-08-11
Lead Sponsor
Vanderbilt University
Target Recruit Count
4
Registration Number
NCT00608465
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes

First Posted Date
2007-12-17
Last Posted Date
2019-09-12
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
17
Registration Number
NCT00574834
Locations
🇺🇸

University of Maryland, Baltimore, Baltimore, Maryland, United States

Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome

First Posted Date
2007-10-11
Last Posted Date
2011-05-24
Lead Sponsor
Novartis
Target Recruit Count
178
Registration Number
NCT00542269
Locations
🇬🇧

Addenbrookes Hospital, Cambridge, United Kingdom

Nephropathy In Type 2 Diabetes and Cardio-renal Events

First Posted Date
2007-09-27
Last Posted Date
2020-08-03
Lead Sponsor
University of Campania "Luigi Vanvitelli"
Target Recruit Count
850
Registration Number
NCT00535925
Locations
🇮🇹

Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy

Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg

Phase 3
Completed
Conditions
Interventions
First Posted Date
2007-09-14
Last Posted Date
2011-03-25
Lead Sponsor
Novartis
Target Recruit Count
1613
Registration Number
NCT00529451
Locations
🇹🇭

Novartis Investigative Sites, Thailand, Thailand

© Copyright 2024. All Rights Reserved by MedPath